Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-05 | Dr. French, Ph.D., is a pharmaceutical industry veteran with over 25 years of experience in pharmaceutical sciences and drug-device combination products. Dr. French, has been Vice President of Dosage Form Design and Development at AstraZeneca since June 2017. Prior to joining AstraZeneca, Dr. French was Senior Director of Device Development at Genentech from January 2009 to May 2017. She was Executive Director of Drug Delivery Engineering at Amgen, Inc. before joining Genentech. For her entire career, Dr. French, has been developing and commercializing drug products, drug delivery systems and devices. She has led the development and commercialization of numerous products with delivery devices worldwide, including auto-injectors, pen injectors, needle stick prevention devices, prefilled syringes, needle-free injectors, subcutaneous infusion devices, intraocular delivery devices, inhalation drug delivery systems, and patient aids and tools for drug preparation and administration. The Audit Committee is currently comprised of Messrs. Anderson (chair), Allen and Fletcher and Ms. Frommer. Each member of this committee is “independent” within the meaning of applicable SEC rules and standards of the Nasdaq Stock Market LLC (the “Nasdaq”). 2020 FISCAL YEAR DIRECTOR COMPENSATION TABLE does not list Donna French, indicating no compensation for 2020. |
| 2022-03-18 | The following table sets forth the name, age and positions of each Director Nominee: Donna French 57 Director (since May 2021). The Audit Committee is currently comprised of Messrs. Anderson (chair), Allen and Beck and Dr. French. The 2021 Fiscal Year Director Compensation Table shows Donna French total compensation of $40,796. |
| 2024-03-28 | Donna French Cash Retainer $50,000 Common Stock Award $60,000 Total $110,000 Committee Membership: Nominating and Corporate Governance Committee Member |
Data sourced from SEC filings. Last updated: 2025-08-30